AEON Biopharma amended its Two-Year Milestone Warrants to reduce the exercise price from approximately $0.32 to $0.20 per share. This change was triggered by an FDA meeting that did not preclude advancing ABP-450 toward a Biologics License Application under the biosimilar pathway, which accelerated the warrants' expiration to November 16, 2026. The company expects to receive approximately $6.2 million in gross proceeds from warrant exercises at the new price. AEON Biopharma is a clinical-stage biotechnology company focused on developing biosimilars.
